In a move to strengthen its worldwide footprint, Brinton Pharmaceuticals Ltd today inaugurated its Global Research and Development Centre in the United Kingdom at The Heath Business and Technical Park in Runcorn.
The new centre was officially opened during a visit by Nigel Huddleston MP, Minister of State at the Department for Business and Trade, in the presence of Brinton Pharma’s Chairman and Managing Director, Mr Rahul Kumar Darda.
Mr Huddleston said: “I am delighted to be inaugurating this new facility in Runcorn, which will help our domestic healthcare sector and create highly skilled jobs. This is an excellent example of the benefits UK-India trade can bring to both nations. By deepening our trading relationship, the UK-India trade deal can pave the way for even more investment opportunities and make it easier for UK and Indian companies, such as Brinton Healthcare UK Ltd, to do business in each other’s countries.”
Guests at the event included the Mayor and Mayoress of Halton, Mark and Andrea Denett; Dr Shashank Vikram, IFS, Consul General of India, Birmingham; John Lewis MBE, Managing Director and owner of SOG Group; Dr Praveen Kumar Tavva, Director & Chief Scientific Officer, Brinton Healthcare UK Ltd and Dr Sonja Vujovic, Head of Consultancy and Innovation at University of Liverpool.
In a welcome address on behalf of SOG, Mr Lewis said: “Brinton announced last year its intention to expand its global operations by moving into to the UK, to create a dedicated research and development centre in the North of England. Naturally we are delighted they chose The Heath, above a number of other science parks, as the perfect location for their new R&D operation.
“The attendance today of the Minister of State for Business and Trade underpins the immense importance of Brinton’s arrival in the UK to our business and science sectors. I know Brinton have exciting plans to expand operations here over the next few years, creating hundreds of new skilled jobs. SOG are happy, willing and able to help them achieve their aspirations.”
Brinton with a global presence spanning across 32 countries sees the R&D Centre at The Heath as a strategic facility that will deepen its ongoing research in the areas of health and life sciences and support the company’s ambition to build next generation healthcare products. The company is planning to invest GBP 30 million over the next five years in the new facility.
“We have developed this facility to meet global standards. We appreciate the continuous support received from the UK Government at every stage. We are optimistic that this R&D Centre will come up with many new drugs that will change human health for the better,” said Mr Darda.
The R&D Centre’s primary focus is on innovations in topical skin delivery systems & focus on studying various skin disorders. “This is one growing segment where the world is looking towards path-breaking medical interventions and result-oriented solutions. We want to make use of this space and offer meaningful interventions,” added Mr Darda.
Welcoming the company to the Liverpool City Region, Mark Basnett, MD at Growth Platform – Liverpool City Region Growth Company, said, “It is fantastic to welcome Brinton Pharmaceuticals, an innovation-led Indian multinational Pharmaceutical Company, to Halton and the wider Liverpool City Region. Their Global R&D Centre is exactly the type of inward investment that we, and our partners, work hard to bring to the region and is further evidence that we remain the natural choice for businesses in the Health & Life Science sector. We look forward to forging a long and successful partnership with them as they continue their global growth.”